Physician profile
Mary Ty
NPI 1003085507
$2,101.68
in general payments reported to CMS, 2019-2025
16 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $240 · 2021: $373 · 2022: $206 · 2023: $357 · 2024: $173 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $607.34 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.13 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $450.36 | 2019-2025 | Rexulti |
| Allergan, INC. | $188.35 | 2019-2020 | |
| Abbott Laboratories | $154.19 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $151.78 | 2020-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $122.00 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $59.46 | 2019-2021 | |
| Neos Therapeutics, Lp | $49.17 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $36.36 | 2022-2023 | Quviviq |
| Alkermes, INC. | $35.66 | 2021-2025 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $32.50 | 2019 | |
| Shire North American Group INC | $28.06 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.54 | 2019 | |
| Lundbeck LLC | $13.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.